z-logo
Premium
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1–infected patients with severe chronic kidney disease
Author(s) -
Sanai Faisal M.,
Alghamdi Abdullah S.,
Afghani Ahmad A.,
Alswat Khalid,
AlZanbagi Adnan,
Alghamdi Mosfer N.,
AlMousa Abdallah,
Aseeri Mohammed,
Assiri Abdullah M.,
Babatin Mohamed A.
Publication year - 2018
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.13674
Subject(s) - ombitasvir , paritaprevir , dasabuvir , ritonavir , medicine , gastroenterology , kidney disease , ribavirin , hepatitis c virus , immunology , viral load , virus , antiretroviral therapy
Background & Aims Limited data have shown high efficacy of co‐formulated ombitasvir/paritaprevir/ritonavir ( OBV / PTV /r) in the treatment of hepatitis C virus ( HCV ) genotype ( GT )‐4, and combined with dasabuvir ( DSV ) in GT 1 patients, with chronic kidney disease ( CKD ) stages 4‐5 (<30 mL/min/1.73 m 2 ). We assessed real‐world safety and efficacy of OBV / PTV /r ±  DSV in GT 1‐ and 4‐infected patients. Methods In this observational cohort (n = 67), we enrolled stages 4‐5 CKD treatment‐naïve or Peginterferon/ RBV ‐experienced  GT 4‐infected patients (n = 32) treated for 12‐24 weeks with OBV / PTV /r ±  RBV , and plus DSV in GT 1 patients (n = 35, including 3 with GT 1/4 co‐infection). RBV was dosed by physician discretion between 200 mg weekly and 200 mg daily. Primary endpoints were SVR 12, calculated on intention‐to‐treat ( ITT ) basis, and occurrence of serious adverse events. Results The mean age of the cohort was 45.7 ± 12.7 years, 50.7% were females, 20.9% had cirrhosis, 35.8% were treatment‐experienced and 97% were on haemodialysis. Three patients (F4) received 24‐week treatment, 2 with GT 4, and 1 with GT 1a; and 19.4% were treated without RBV , including 9 GT 1, and 4 GT 4. Overall, 65 (97.1%) patients achieved SVR 12, including 100% of those with a post‐treatment follow‐up (modified ITT analysis). Of the two patients without SVR 12, one died from sepsis‐related complications and the other from a myocardial infarction 2 weeks after completing therapy. Grades 3‐4 anaemia occurred in 8.9%. Conclusion A 12‐week regimen of OBV / PTV /r ±  DSV with or without RBV is highly effective with a favourable safety profile amongst GT 4 and GT 1 patients with CKD stages 4‐5. SVR 12 rates were high regardless of patient characteristics.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here